Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

American Heart Journal

Volumn 160, Issue 3, 2010, Pages 487.e1-487.e7

  Cadeddu, Christian ^a   Piras, Alessandra ^a   Mantovani, Giovanni ^a   Deidda, Martino ^a   Dessì, Mariele ^a   Madeddu, Clelia ^a   Massa, Elena ^a   Mercuro, Giuseppe ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; PLACEBO; REACTIVE OXYGEN METABOLITE; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTINEOPLASTIC ANTIBIOTIC; AUTACOID; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CYTOKINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART MUSCLE INJURY; HUMAN; HYPOTENSION; INFLAMMATION; MALE; NEUTROPENIA; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TISSUE DOPPLER IMAGING; BLOOD; CHEMICALLY INDUCED; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; HEART; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIBIOTICS, ANTINEOPLASTIC; BENZIMIDAZOLES; BENZOATES; CYTOKINES; ECHOCARDIOGRAPHY, DOPPLER; EPIRUBICIN; FEMALE; HEART; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77956363811     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.05.037     Document Type: Article

References (36)

1. Fuster V., Gersh B.J., and Giuliani E.R. The natural history of idiopathic dilated cardiomyopathy Am J Cardiol 47 1981 525 531
2. Kaklamani V.G., and Gradishar W.J. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 4 Suppl 1 2003 S26 S33
3. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines Semin Oncol 33 3 Suppl 8 2006 S2 S7
4. Kilickap S., Barista I., and Akgul E. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity Ann Oncol 16 2005 798 804
5. Mercuro G., Cadeddu C., and Piras A. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers Oncologist 12 2007 1124 1133
6. Jensen B.V., Skovsgaard T., and Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients Ann Oncol 13 2002 699 709
7. Toko H., Oka T., and Zou Y. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy Hypertens Res 25 2002 597 603
8. Soga M., Kamal F.A., and Watanabe K. Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats Int J Cardiol 110 2006 378 385
9. Nakamae H., Tsumura K., and Terada Y. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 2005 2492 2498
10. Kalay N., Basar E., and Ozdogru I. Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
11. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
12. Jassal D.S., Han S.Y., and Hans C. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy J Am Soc Echocardiogr 22 2009 418 424
13. Cho G.Y., Marwick T.H., and Kim H.S. Global 2-dimensional strain as a new prognosticator in patients with heart failure J Am Coll Cardiol 54 2009 618 624
14. Oken M.M., Creech R.H., and Tormey D.C. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
15. Jensen B.V. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer Semin Oncol 33 3 Suppl 8 2006 S15 S21
16. Mantovani G., Madeddu C., and Cadeddu C. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers Oncologist 13 2008 1296 1305
17. Jalowy A., Schulz R., and Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion Basic Res Cardiol 93 Suppl 2 1998 85 91
18. Ferreira A.L., Matsubara L.S., and Matsubara B.B. Anthracycline-induced cardiotoxicity Cardiovasc Hematol Agents Med Chem 6 2008 278 281
19. Rosenthal T., and Gavras I. Angiotensin inhibition and malignancies: a review J Hum Hypertens 23 2009 623 635
20. Uemura H., Nakaigawa N., and Ishiguro H. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer Curr Cancer Drug Targets 5 2005 307 323
21. Escobar E., Rodriguez-Reyna T.S., and Arrieta O. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer Curr Vasc Pharmacol 2 2004 385 399
22. Iqbal M., Dubey K., and Anwer T. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats Pharmacol Rep 60 2008 382 390
23. Tuck M.L. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system Curr Hypertens Rep 7 2005 240 243
24. Yamagishi S., and Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property Med Hypotheses 64 2005 476 478
25. Torre-Amione G., Kapadia S., and Lee J. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart Circulation 93 1996 704 711
26. Satoh M., Nakamura M., and Akatsu T. C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy Eur J Heart Fail 7 2005 748 754
27. Mantovani G., Maccio A., and Madeddu C. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status Int J Cancer 98 2002 84 91
28. Minotti G., Menna P., and Salvatorelli E. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229
29. Conklin K.A. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity Integr Cancer Ther 4 2005 110 130
30. Kaur K., Sharma A.K., and Dhingra S. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes J Mol Cell Cardiol 41 2006 1023 1030
31. Kaiserova H., Simunek T., and Sterba M. New iron chelators in anthracycline-induced cardiotoxicity Cardiovasc Toxicol 7 2007 145 150
32. van Acker S.A., Boven E., and Kuiper K. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin Clin Cancer Res 3 1997 1747 1754
33. Wu X., Patel D., and Hasinoff B.B. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin J Inorg Biochem 98 2004 1818 1823
34. Swain S.M., Whaley F.S., and Gerber M.C. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 1997 1318 1332
35. Xiong X., Ye Y., and Fu L. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines Invest New Drugs 27 2009 223 232
36. Cianchetti S., Del F.A., and Colognato R. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells Atherosclerosis 198 2008 22 28